24 Oct

Bayezian's Approach to Breast Cancer Survival Prediction

Resource

Introduction

Bayezian's Approach to Breast Cancer Survival Prediction: Leveraging AI and Machine Learning on Genomic Data While Navigating Pitfalls

Read the white paper below
Quick links
No items found.

New Releases

Resource
24 Oct

Three Questions for Data Privacy Week With the rapid rise in generative AI and large language models (LLMs),

Three Questions for Data Privacy Week With the rapid rise in generative AI and large language models (LLMs), Data Privacy Week 2024 is set to be more crucial than ever, highlights Ben Wells, head of statistical data science at Bayezian. The New York Times' lawsuit against Microsoft and OpenAI for allegedly using copyrighted material to train ChatGPT underscores significant concerns about AI training data. OpenAI admits that training their models would be impossible without copyrighted content, raising questions about fair compensation for content creators. Despite OpenAI's substantial revenue, creators have yet to see any financial benefits, leading to a growing call for LLM models to pay for the data they use. However, determining the right compensation remains challenging due to the complex nature of data usage in AI training. Privacy concerns extend beyond training data to how AI models collect and use personal information during interactions. AI tools learn and improve based on user input, making it critical for data to be anonymized, securely stored, and deleted after use. Transparency around data usage is necessary, as is giving users control over their data. The ethical management of AI's growth is essential, requiring companies to implement robust safeguards against misuse. While the EU AI Act is a promising step towards regulating AI, global cooperation is needed to ensure consistent and effective governance, preventing companies from evading regulations by relocating.
Resource
24 Oct

Generative AI and the Copyright Conundrum In late 2023

Generative AI and the Copyright Conundrum In late 2023, The New York Times sued OpenAI and Microsoft for copyright infringement, highlighting the ongoing conflict between generative AI and copyright laws. As large language models (LLMs) rely on data from published works for training, this lawsuit marks a pivotal moment in addressing these issues. The EU AI Act aims to regulate AI use by demanding transparency and prohibiting certain applications, but enforcement may take years. The delicate balance between protecting intellectual property and fostering AI innovation remains unresolved, with developers, publishers, and lawmakers struggling to find common ground. OpenAI's response to the lawsuit, expressing surprise and disappointment, underscores the tension in this debate. Despite their efforts to reduce content "regurgitation," creators remain dissatisfied. OpenAI's plea for special treatment in licensing fees, arguing AI development is impossible without copyrighted materials, has been met with criticism. The proposed solution is for AI developers to pay for using copyrighted content, akin to music licensing in public spaces. As legal battles unfold, foundational AI developers will likely be compelled to compensate creators, raising costs and challenging the current state of AI attribution. The future may require new regulatory bodies to ensure fair and effective management of AI's integration into society.

“Bayezian brought us scalable AI that felt native to our workflows. No reengineering, no hype — just capability that delivers from day one.”

Scalable Intelligence, Zero Hype

“They’re not just building models. Bayezian solves real, high-stakes problems with domain-aware intelligence — delivered with speed and clarity.”

Complex Problem Solving

“Bayezian’s ability to embed AI into our existing systems without disruption is what sets them apart. They don’t just provide insights — they operationalize them.”

Embedded AI Integration

“The Bayezian team doesn’t just build smart tools — they see where the future of clinical operations is going. We’re betting on their vision.”

Leadership & Vision

“We’ve worked with a lot of vendors, but Bayezian actually understands data standards like CDISC and turns that into automation we can trust.”

Trial Design Reuse & Data Standards

“Being part of the Bayezian incubator gave us more than tech — it gave us a strategic advantage. They understand clinical trials, not just AI.”

The Incubator Experience

“Bayezian nailed our enrollment risk 8 weeks before we would’ve noticed. Their AI forecasting helped us de-risk a high-stakes trial with minimal effort from our team.”

Patient Recruitment Forecasting

“The ability to auto-generate structured safety narratives and protocol summaries is a game-changer. Bayezian’s models are domain-aware — not generic.”

Scientific & Regulatory Content Generation

“What used to take our ops team days to forecast now takes minutes. Bayezian’s platform showed us how embedded AI can drive real-time decision-making without overhauling our systems.”

Site Operations & Resource Planning

“Bayezian helped us catch protocol deviations weeks before our monitors could. Their AI didn’t just flag issues — it gave us the why and the where, embedded right into our workflow.”

Protocol Compliance Monitoring

Get in touch.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.